• 1
    HCUP Nationwide Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ), 2003. Available at
  • 2
    Yoneyama K, Nebashi Y, Kiuchi Y, Shibata M, Mitamura K. Prognostic index of cirrhotic patients with hepatic encephalopathy with and without hepatocellular carcinoma. Dig Dis Sci 2004; 49: 117480.
  • 3
    Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40: 82330.
  • 4
    Groeneweg M, Quero JC, De Bruijn I, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998; 28: 459.
  • 5
    Li YY, Nie YQ, Sha WH, et al. Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China. World J Gastroenterol 2004; 10: 2397401.
  • 6
    Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol 2001; 96: 271823.
    Direct Link:
  • 7
    Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 5315.
  • 8
    Marottoli RA, Cooney LM Jr, Wagner R, Doucette J, Tinetti ME. Predictors of automobile crashes and moving violations among elderly drivers. Ann Intern Med 1994; 121: 8426.
  • 9
    Cordoba J, Lucke R. Driving under the influence of minimal hepatic encephalopathy. Hepatology 2004; 39: 599601.
  • 10
    Wein C, Koch H, Popp B, Oehler G, Schauder P. Minimal hepatic encephalopathy impairs fitness to drive. Hepatology 2004; 39: 73945.
  • 11
    Watanabe A, Tuchida T, Yata Y, Kuwabara Y. Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability. Metab Brain Dis 1995; 10: 23948.
  • 12
    Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev (Online) 2004; CD003044.
  • 13
    Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39: 5425.
  • 14
    Venturini AP, Marchi E. In vitro and in vivo evaluation of L/105, a new topical intestinal rifamycin. Chemioterapia 1986; 5: 25762.
  • 15
    Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 46784.
  • 16
    Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 (Suppl. 1): 3666.
  • 17
    Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46: 399407.
  • 18
    Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 5766.
  • 19
    Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993; 4: 718.
  • 20
    Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy; results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54: 598609.
  • 21
    Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 10918.
  • 22
    Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 2038.
  • 23
    Fleming T. 2006 Red Book. Montvale, NJ: Thompson Medical Economics, 2006.
  • 24
    Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 196876.
    Direct Link:
  • 25
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 120836.
  • 26
    Carithers RL Jr. Liver transplantation. American Association for the Study of Liver Diseases. Liver Transpl 2000; 6: 12235.
  • 27
    Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 1997; 92: 108191.
  • 28
    Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 84156.
  • 29
    Murray KF, Carithers RL Jr. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 140732.
  • 30
    United Network for Organ Sharing. Available at, accessed on December 2006.
  • 31
    Gold MR, Siegel JE, Russell LB, Weinstein MG. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
  • 32
    Chong CA, Gulamhussein A, Heathcote EJ, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 6308.
    Direct Link:
  • 33
    Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 207689.
    Direct Link:
  • 34
    Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 82131.
  • 35
    Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 132937.
  • 36
    Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 127085.
  • 37
    Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997; 92: 217987.
  • 38
    West DS, Johnson JT, Hong SH. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan. J Manag Care Pharm 2006; 12: 2532.
  • 39
    Trueman P, Drummond M, Hutton J. Developing guidance for budget impact analysis. PharmacoEconomics 2001; 19: 60921.
  • 40
    Mauskopf JA, Earnshaw SR, Mullins C. Budget impact analysis: review of the state of the art. Expert Rev Pharmacoeconomics Outcomes Res 2005; 5: 6579.
  • 41
    Dufour MC. Chronic liver disease and cirrhosis. In: EverhartJE, ed. Digestive Diseases in the United States: Epidemiology and Impact, Washington, DC: US Dept of Health and Human Services: NIH publication, 1994: 61545.
  • 42
    American Medical Association. AMA CPT Code Book. Chicago: American Medical Association, 2006.
  • 43
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 85565.
  • 44
    United States Department of Labor Bureau of Labor Statistics. Consumer Price Index Calculator. Available at:, accessed on December 2006.
  • 45
    Meunnig P. Designing and Conducting Cost-Effectivenss Analyses in Medicine and Health Care. San Francisco: Jossey-Bass, 2002.
  • 46
    Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377401.
  • 47
    Spiegel BMR, Lim B, Mann N, Dulai GS, Gralnek IM. The cost-effectiveness of intravenous versus oral proton pump inhibitor therapy in the management of peptic ulcer hemorrhage: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2006; 4: 98897.
  • 48
    Pharmacy Benefit Report Facts and Figures. East Hanover, NJ: Novartis Pharmaceuticals, 2003.
  • 49
    Cooke CE, Wong W, Lee H. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J Manag Care Pharm 2005; 11: 67480.
  • 50
    Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 5362.
  • 51
    Di Piazza S, Gabriella Filippazzo M, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23: 4037.
  • 52
    Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 1758.
  • 53
    Spiegel BM, Targownik L, Dulai GS, Gralnek IM. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003; 138: 795806.
  • 54
    Spiegel BM, Targownik L, Dulai GS, Karsan HA, Gralnek IM. Endoscopic screening for esophageal varices in cirrhosis: is it ever cost effective? Hepatology 2003; 37: 36677.
  • 55
    Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 57383.
  • 56
    Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 1987; 15: 33543.
  • 57
    Orlandi F, Freddara U, Candelaresi MT, et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981; 26: 498506.
  • 58
    Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970; 59: 82732.
  • 59
    Germain L, Frexinos J, Louis A, Ribet A. Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt. Arch Fr Mal App Dig 1973; 62: 293302.
  • 60
    Messner M, Le Gall J, Toulouse P, Javaudin L, Delamaire D, Brissot P. Plasma ratio of branched chain/aromatic amino acids during treatment of chronic hepatic encephalopathy using lactulose/bromocriptine in a double blind procedure [abstract]. Liver 1982; 2: 312.
  • 61
    Fiaccadori F, Ghinelli F, Pedretti G, Pelosi G, Sacchini D, Zeneroli ML. Branched chain amino acid enriched solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital J Gastroenterol 1985; 17: 510.
  • 62
    Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio Blanco C, Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 1995; 23: 3946.
  • 63
    Li Z, Zhang H, Hong Y. Clinical effect of lactulose in the treatment of subclinical hepatic encephalopathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 1999; 9: 135.
  • 64
    Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology 1997; 26: 14104.
  • 65
    Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci 2000; 45: 154952.
  • 66
    Morgan MY, Hawley KE, Stambuk D. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study. J Hepatol 1987; 4: 23644.
  • 67
    Riggio O, Balducci G, Ariosto F, et al. Lactitol in the treatment of chronic hepatic encephalopathy – a randomized cross-over comparison with lactulose. Hepatogastroenterology 1990; 37: 5247.
  • 68
    Riggio O, Balducci G, Ariosto F, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci 1989; 34: 8239.
  • 69
    Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 1985; 26: 41520.
  • 70
    Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD. Treatment of porto-systemic encephalopathy with lactitol versus lactulose: a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei); 1995; 55: 316.
  • 71
    Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol 1989; 8: 20817.
  • 72
    Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13: 593601.
  • 73
    Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11: 38792.
  • 74
    Elkington SG, Floch MH, Conn HO. Lactulose in the treatment of chronic portal-systemic encephalopathy. A double-blind clinical trial. N Engl J Med 1969; 281: 40812.
  • 75
    Rodgers JB Jr, Kiley JE, Balint JA. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol 1973; 60: 45965.
  • 76
    Heredia D, Teres J, Orteu N, Rodes J. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. J Hepatol 1988; 7: 10610.
  • 77
    Tarao K, Ikeda T, Hayashi K, et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31: 7026.
  • 78
    Russo M, Galanti B, Nardiello S, Pizzella T, Ronga C, Guiusti G. Ribostamycin for the treatment of hepatic encephalopathy. Curr Ther Res Clin 1989; 45: 13141.
  • 79
    Horsmans Y, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther 1997; 11: 16570.
  • 80
    Nie YQ, Zeng Z, Li YY, Sha WH, Ping L, Dai SJ. Long-term efficacy of lactulose in patients with subclinical hepatic encephalopathy. Zhonghua Nei Ke Za Zhi (Chinese J Int Med) 2003; 42: 2613.
  • 81
    Uribe M, Toledo H, Perez F, et al. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial. Dig Dis Sci 1987; 32: 134553.
  • 82
    Salerno F, Moser P, Maggi A, Vitaliani G, Benetti G. Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. J Hepatol 1994; 21: 10926.
  • 83
    Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995; 13: 27481.
  • 84
    Parini P, Cipolla A, Massimo R, Salzetta A, Mazzella G, Roda E. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 1992; 52: 3429.
  • 85
    Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 518.
  • 86
    Quero JC, Hartmann IJ, Meulstee J, Hop WC, Schalm SW. The diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis using neuropsychological tests and automated electroencephalogram analysis. Hepatology 1996; 24: 55660.
  • 87
    Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol 2000; 95: 202934.
    Direct Link:
  • 88
    D’Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 46875.
  • 89
    Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 26370.
  • 90
    Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 7449.
  • 91
    Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 7782.
  • 92
    Gentilini P, Laffi G, La Villa G, et al. Long course and prognostic factors of virus-induced cirrhosis of the liver. Am J Gastroenterol 1997; 92: 6672.
  • 93
    Weissberg JI, Andres LL, Smith CI, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 6136.
  • 94
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 30613.
  • 95
    Sulaiman HA. The development of hepatocellular carcinoma from liver cirrhosis during a follow-up study. Gastroenterol Jpn 1989; 24: 56772.
  • 96
    Viola LA, Barrison IG, Coleman JC, et al. Natural history of liver disease in chronic hepatitis B surface antigen carriers. Survey of 100 patients from Great Britain. Lancet 1981; 2: 11569.
  • 97
    De Jongh FE, Janssen HL, De Man RA, Hop WC, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 16305.
  • 98
    Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 25764.